Understanding the use of IL12/IL23 targeted biologics

(22:5)

Safety and Efficacy of IL-23 Inhibitors in Plaque Psoriasis

(4:12)

New Biologic Therapies that Target the IL-12/23 Pathway

(23:55)

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

(7:16)

Use of IL-23 Inhibitors to Treat Plaque Psoriasis

(5:11)

Treating Plaque Psoriasis: IL-17 and IL-23 Inhibitors

(5:19)

Targeting IL-12/IL-23 in Crohn’s Disease

(4:17)

Visualizing the Future: Advances in IL-23-Targeteding Therapies in the Treatment of IBD

(1:25:32)

IL-23 Inhibitors and Other Emerging Psoriasis Treatments

(24:2)

Psoriasis and beyond: targeting the IL-17 pathway

(5:50)

IL-23s: Psoriasis therapy overview

(1:51)

Advances in Anti-Cytokine Therapy: New Pathways (IL 12/23, IL17, IL23)

(19:57)

WCH23: IL-17 vs IL-23 Blockers – Why and When?

(3:24)

IL23 Inhibitors and COVID-19

(4:58)

The role of Il-23 in Autoimmunity

(2:47)

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhD

(7:49)

IL23 \u0026 IL12/23 Inhibitors: An Overview

(2:34)

PsA Perspectives - IL-23: Dr. Eric Ruderman

(3:41)

Interleukin Inhibitors and Risk of Cancer, Serious or Opportunistic Infections

(3:27)

IL-17 Inhibitors for Plaque Psoriasis and IBD

(3:18)